Andras G. Lacko

Dr. Lacko’s research focuses on the development and characterization of a lipoprotein based drug delivery system (rHDL), based on a list of beneficial characteristics for rHDL, anticipating this drug delivery model to be superior to existing technologies. Proof of concept studies so far supported these expectations and efforts are under way to translate the rHDL platform toward clinical and commercial applications. Dr. Lacko has published over 100 papers in refereed journals, he has organized several international meetings, has been a reviewer (37 scientific and medical journals and several grant funding organizations). He currently serves on a review panel for the European Research Council.